Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

New X-ray delivery method could improve radiation therapy

DOE/Brookhaven National Laboratory : 19 April, 2007  (Technical Article)
Researchers at the U.S. Department of Energy
Results on the improved method, which was tested in rats, will be published online this week by the Proceedings of the National Academy of Sciences.

The technique, microbeam radiation therapy, previously used a high-intensity synchrotron x-ray source such as a superconducting wiggler at Brookhaven’s National Synchrotron Light Source to produce parallel arrays of very thin (25 to 90 micrometers) planar x-ray beams (picture the parallel panels of window blinds in the open position) instead of the unsegmented (solid), broad beams used in conventional radiation treatment. Previous studies conducted at Brookhaven and at the European Synchrotron Radiation Facility in Grenoble, France, demonstrated MRT’s ability to control malignant tumors in animals with high radiation doses while subjecting adjacent normal tissue to little collateral damage.

But the technique has limitations. For one thing, only certain synchrotrons can generate its very thin beams at adequate intensity, and such facilities are available at only a few research centers around the world.

“The new development seeks a way out of this situation,” explained Brookhaven scientist Avraham Dilmanian, lead author of the new study. In this paper, the scientists report results that demonstrate the potential efficacy of significantly thicker microbeams, as well as a way to “interlace” the beams within a well-defined “target” inside the subject to increase their killing potential there, while retaining the technique’s hallmark feature of sparing healthy tissue outside that target.

First, they exposed the spinal cords and brains of healthy rats to thicker (0.27 to 0.68 millimeter) microbeams at high doses of radiation and monitored the animals for signs of tissue damage. After seven months, animals exposed to beams as thick as 0.68 millimeter showed no or little damage to the nervous system.

“This demonstrates that the healthy-tissue-sparing nature of the technique stays strong at a beam thickness that is within a range that could be produced by specialized x-ray tubes of extremely high voltage and current,” Dilmanian said. Such x-ray sources may become available sometime in the future and may allow the implementation of the method in hospitals.

Next, the scientists demonstrated the ability to “interlace” two parallel arrays of the thicker microbeams at a 90-degree angle to form a solid beam at a small target volume in the rats’ brains, and measured the effects of varying doses of radiation on the targeted tissue volume and the surrounding tissue using magnetic resonance imaging scans. For interlacing, the gaps between the beams in each array were chosen to be the same as the thickness of each beam, so the beams from one array would fill the gaps in the other to produce the equivalent of an unsegmented beam in the target volume only.

“In this way we are effectively delivering an unsegmented broad beam type of dose to just the target region, which could be a tumor, or a non-tumerous target we want to ablate, while exposing the surrounding tissue to segmented radiation from which it can recover,” Dilmanian said.

The MRI scans showed that at a particular dose of radiation, the new configuration could produce major damage to the target volume but virtually no damage beyond the target range. “The dose of radiation delivered to the target volume would have been enough to ablate a malignant tumor,” Dilmanian said.

“These results show that thick microbeams generated by special x-ray tubes in hospitals could eventually be used to destroy selective targets while sparing healthy tissue,” Dilmanian said.

Said collaborator Eliot Rosen, a radiation oncologist at Lombardi Comprehensive Cancer Center, Georgetown University, “This form of microbeam radiation therapy could improve the treatment of many forms of cancer now treated with radiation, because it can deliver a more lethal dose to the tumor while minimizing damage to surrounding healthy tissue. It may also extend the use of radiation to cases where it is now used only judiciously, such as brain cancer in patients under three years of age, because of the high sensitivity of young brain tissue to radiation.”

And according to collaborators David Anschel, a neurologist at Stony Brook University and Brookhaven Lab, and Pantaleo Romanelli, a neurosurgeon from NEUROMED Medical Center, the technique may also have applications in treating a wide range of benign and malignant brain tumors and other functional brain disorders such as epilepsy and Parkinson’s disease.

MRT research was initiated by retired Brookhaven scientist Daniel Slatkin, the late Per Spanne, also from Brookhaven, Dilmanian, and others in the early 1990s at Brookhaven’s NSLS. Since the mid 1990s, the method has been under ongoing investigation also at ESRF.

It is not clear why high dose MRT is effective at killing tumor tissue while sparing healthy tissue. The researchers hypothesize that the normal tissue repairs itself, in part, as a result of the survival between the microbeams of the microvasculature’s angiogenic cells. This effect seems to occur more successfully in the normal tissue than in tumors, although other factors also seem to be involved.

Neither the original nor the improved MRT technique has been tested in humans.

The MRT research program at Brookhaven was funded in the past by Brookhaven’s Laboratory Directed Research and Development program, the Children’s Brian Tumor Foundation, the Office of Biological and Environmental Research within the U.S. Department of Energy’s Office of Science, and by the National Institutes of Health. The studies were carried out at the NSLS, which is supported by the Office of Basic Energy Sciences within DOE’s Office of Science.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo